Search - tctmd.com

Displaying 221 - 237 of 237

Sort: Relevancy | Date

News Conference News TCT 2013

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

October 28, 2013

News Daily News

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Yael L. Maxwell

March 09, 2013

News Daily News

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Yael L. Maxwell

March 09, 2013

News Conference News TCT 2012

Stroke Prevention Strategies Discussed

October 26, 2012

News Conference News ESC 2012

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Caitlin E. Cox

August 27, 2012

News Daily News

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Jason Kahn

June 22, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Daily News

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Caitlin E. Cox

August 10, 2011

News Daily News

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

June 24, 2011

Advertisement

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Stroke Prevention Strategies Discussed

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Hope Renewed for Novel Anticoagulant Use in ACS

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Novel Anticoagulants Showing Benefits in A-fib Subgroups

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content